ARTICLE | Tools & Techniques

New CRISPR case to finally settle the score

How the latest interference between Broad and UC could shake up the landscape of CRISPR therapies

July 25, 2019 10:49 PM UTC

The latest CRISPR patent case aims to do what the first didn’t: determine who gets rights to the gene editing technology in eukaryotic cells, a category that covers almost all the cell types that matter to drug developers.

The outcome is likely to shake up the IP rights of CRISPR companies, with the stakes highest for the most advanced biotechs whose therapies rely on CRISPR-Cas9, the foundational technology...